drug
everolimus ODT
Marketedupdated 6mo agoby Biocon Pharma Ltd
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- drugeverolimus SR36 co-mentions · 24 sources
- drugZortress36 co-mentions · 24 sources
- drugEVEROLIMUS36 co-mentions · 24 sources
- tagApproval16 co-mentions · 8 sources
- tagAdCom15 co-mentions · 11 sources
- tagPMA Approval15 co-mentions · 11 sources
- tagSmall Molecule8 co-mentions · 8 sources
- companyPar Pharmaceutical Inc5 co-mentions · 5 sources
all catalysts(0)
nothing on the calendar yet
Trials studying everolimus ODT
- phase4A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)
- phase2A Prospective, Phase II, Exploratory Study Protocol of a Chemotherapy Sensitivity-based Culmerciclib Combination Regimen in Neoadjuvant Therapy for HR+/HER2- Breast Cancer.
- phase3Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- phase1Phase I Trial of VS-6766 Alone and in Combination With Everolimus
- phase3A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
- phase2Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer
- phase2A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
- phase3Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
News(3)
- FDA rejects ITM Isotope’s radiopharma therapy over manufacturing issuesITM Isotope Technologies plans on resubmitting its advanced cancer radiopharma therapy to the FDA after addressing the agency’s concerns.biospace · 3mo ago
- STAT+: In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatmentThe FDA has rejected a radiopharmaceutical therapy because of manufacturing issues, halting what would have been a competitor for Novartis.stat · 3mo ago
- Opinion: I’m a heart transplant recipient. I’m haunted by ‘ghost approval’ for medication I need to survive“On paper, I have insurance coverage. In real life, I don’t have access. That’s what I call ‘ghost approval,’” writes patient advocate Payton Herres.stat · 6mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that